The impact of the HIV reverse transcriptase M184V mutation in combination with single thymidine analogue mutations on nucleoside reverse transcriptase inhibitor resistance in clinical samples from a large patient database

被引：0

作者：

Ross, L

Parkin, N

Bates, M

Fisher, R

St Clair, M

Tisdale, M

Lanier, R

机构：

[1] GlaxoSmithKline Inc, Res Triangle Pk, NC USA

[2] GlaxoSmithKline Inc, Stevenage, Herts, England

来源：

ANTIVIRAL THERAPY | 2003年 / 8卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

141

引用

页码：U134 / U135

页数：2

共 50 条

[31] Epidemiological and Biological Evidence for a Compensatory Effect of Connection Domain Mutation N348I on M184V in HIV-1 Reverse Transcriptase
von Wyl, Viktor
Ehteshami, Maryam
Symons, Jori
Buergisser, Philippe
Nijhuis, Monique
Demeter, Lisa M.
Yerly, Sabine
Boeni, Juerg
Klimkait, Thomas
Schuurman, Rob
Ledergerber, Bruno
Goette, Matthias
Guenthard, Huldrych F.
JOURNAL OF INFECTIOUS DISEASES, 2010, 201 (07): : 1054 - 1062
[32] Novel drug resistance pattern associated with the mutations K70G and M184V in human immunodeficiency virus type 1 reverse transcriptase
Bradshaw, D.
Malik, S.
Booth, C.
Van Houtte, M.
Pattery, T.
Waters, A.
Ainsworth, J.
Geretti, A. M.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (12) : 4489 - 4491
[33] Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations
Deval, J
White, KL
Miller, MD
Parkin, NT
Courcambeck, J
Halfon, P
Selmi, B
Boretto, J
Canard, B
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (01) : 509 - 516
[34] The influence of 3TC-resistance mutations E89G and M184V in the human immunodeficiency virus reverse transcriptase on mispair extension efficiency
Hamburgh, ME
Drosopoulos, WC
Prasad, VR
NUCLEIC ACIDS RESEARCH, 1998, 26 (19) : 4389 - 4394
[35] Prevalence of K65R in different HIV-1 subtypes and its association with thymidine analogue mutations and non-nucleoside reverse transcriptase inhibitor related mutations
Grossman, Z.
Theys, K.
Carvalho, A. P.
Ram, D.
Deforche, K.
Rudich, H.
Vercauteren, J.
Libin, P.
Mendelson, E.
Camaho, R. J.
Levy, I.
Vandamme, A-M
ANTIVIRAL THERAPY, 2008, 13 (04) : A56 - A56
[36] Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance
Buckton, A. J.
Prabhu, D.
Motamed, C.
Harris, R. J.
Hill, C.
Murphy, G.
Parry, J. V.
Johnson, J. A.
Lowndes, C. M.
Gill, N.
Pillay, D.
Cane, P. A.
HIV MEDICINE, 2011, 12 (04) : 250 - 254
[37] Deep sequencing does not reveal additional transmitted mutations in patients diagnosed with HIV-1 variants with single nucleoside reverse transcriptase inhibitor resistance mutations
Pingen, M.
van der Ende, M. E.
Wensing, A. M.
el Barzouhi, A.
Simen, B. B.
Schutten, M.
Boucher, C. A. B.
HIV MEDICINE, 2013, 14 (03) : 176 - 181
[38] The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates
Diallo, K
Brenner, B
Oliveira, M
Moisi, D
Detorio, M
Götte, M
Wainberg, MA
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) : 2376 - 2379
[39] Effects of M184V mutation in multi-dideoxynucleoside analog resistant HIV-1 reverse transcriptase on removal of β-D-dioxolane-guanine monophosphate from blocked primer
Lennerstrand, J
Espili, NH
Pavlova, A
Chu, CK
Asif, G
Schinazi, RF
ANTIVIRAL THERAPY, 2005, 10 : S79 - S79
[40] Effects of M184V mutation in multi-dideoxynucleoside analog resistant HIV-1 reverse transcriptase on removal of β-D-dioxolane-guanine monophosphate from blocked primer
Lennerstrand, J
Espili, NH
Pavlova, A
Chu, CK
Asif, G
Schinazi, RF
ANTIVIRAL THERAPY, 2005, 10 (04) : S79 - S79

← 1 2 3 4 5 →